Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles
- Exelixis will utilize Adagene’s proprietary SAFEbody™ technology to develop novel masked antibody-drug conjugates (ADCs)…